Basilea Pharmaceutica valuation

BSLN · SIX · CHF

Compare Basilea Pharmaceutica
CHF 72.80Change from previous close: +0.14%Absolute change: +CHF 0.10

Close · November 20, 2026

Valuation

The P/E ratio is 18.1. The average price target of 5 analysts is CHF 99.62.

Data as of November 21, 2026

Basilea Pharmaceutica compared with similar companies

Basilea Pharmaceutica's P/E (trailing 12 months): 18.1, +23% against the median of a group of 7 similar companies (14.7).

Basilea Pharmaceutica's metrics compared with similar companies
MetricBasilea PharmaceuticaMedian25th–75th percentileBand
P/E (trailing 12 months)18.114.74.92 – 28.1Middle
Forward P/E12.652.319.9 – 96.9Low
EV/EBITDA13.313.312.4 – 15.8Middle
Price/book5.554.452.62 – 5.35High
Price/sales3.644.203.13 – 22.7Middle
Gross margin38.5%87.2%71.5% – 93.2%Low
Operating margin24.2%19.6%-70.7% – 36.9%Middle
Net margin21.2%10.5%0.0% – 43.9%Middle
ROE39.5%16.3%-5.5% – 27.7%High
Debt/equity0.510.050.03 – 0.34High

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Basilea Pharmaceutica: valuation over time

On the latest fiscal year's earnings (2025), Basilea Pharmaceutica's P/E today is 23.2, below the median of its last 4 fiscal years (29.2; between 7.10 and 44.9 from 2022 to 2025). Relative to earnings, the stock costs less than it used to.

Basilea Pharmaceutica P/E and dividend yield at each fiscal year end
Fiscal yearPrice at year endEarnings per shareP/E
2025CHF 54.70CHF 3.1417.4
2024CHF 41.35CHF 5.827.10
2023CHF 35.30CHF 0.8641.0
2022CHF 45.80CHF 1.0244.9
2021CHF 40.92-CHF 0.58—
2020CHF 53.15-CHF 1.43—
2019CHF 46.86-CHF 2.08—
2018CHF 39.96-CHF 2.89—
2017CHF 75.90-CHF 1.79—
2016CHF 73.10-CHF 5.07—

TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.

TickerLandia analysisHow it is calculated

Other metrics

Valuation multiples

Market cap
CHF 901.05M
Enterprise value
CHF 812.09M
PEG
-0.08
EV/revenue
3.28

Profitability and growth

ROA
13.7%
ROIC
16.8%
Revenue growth (year over year)
14.5%
Earnings growth (year over year)
64.4%

Financial health

Total cash
CHF 173.05M
Total debt
CHF 83.44M
Current ratio
6.60
Quick ratio
5.81
Altman Z-Score
1.21
Piotroski F-Score
6.00

Dividends

Payout ratio
0.0%
Ex-dividend date
April 11, 2013

Analysts and estimates

Average price target
CHF 99.62
Median price target
CHF 110.00
High price target
CHF 126.10
Low price target
CHF 67.00
Analysts with a price target
5
Consensus
Buy
Forward EPS
CHF 5.76
EPS estimate, current year
CHF 6.59

Shares and trading

Beta
0.32
Average volume
44.78K
Shares outstanding
12.39M
Float
11.31M
Institutional ownership
30.7%
Insider ownership
0.6%